Compare Amgen, Inc. (AMGN) vs J M Smucker Co (SJM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs J M Smucker Co — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while J M Smucker Co trades at $111.64 (market cap $11.93B). The key difference: Amgen, Inc. is far larger — about 16.4× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.94%). Which is the better fit depends on your goals.
| AMGN | SJM | |
|---|---|---|
Market Cap | $196.12B | $11.93B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $117.05 |
52-Week Low | $271.18 | $89.53 |
Enterprise Value | $241.41B | $18.96B |
Dividend Yield | 2.77% | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SJM trades at $111.60, up 0.66% today, with technical indicators showing a bearish bias despite recent earnings beats. The company reported a net loss of $1.23 billion in 2025, though revenue grew to $8.73 billion. Analyst consensus is bullish with a $122.92 price target, but weak profitability metrics and high debt levels pose challenges. Recent news highlights mixed sentiment, with some outlets praising growth potential while others caution on sales pressure.
The outlook hinges on margin recovery in coffee and growth in Uncrustables, but fiscal 2027 sales guidance of a 3-4% decline tempers optimism. Risks include competitive pressures and debt management, while the 4% dividend yield offers income support. Upside depends on execution against muted growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
